Evofem breaks free, carving its path through birth-control market chaos.
Evofem Biosciences, the San Diego-based women’s health startup, has agreed to sell itself to biotech firm Aditxt for $100 million. Adixt will also assume some of Evofem’s debt. Evofem’s main product, a